Organovo Holdings, Inc. (ONVO)
$
2.04
+0.03 (1.47%)
Key metrics
Financial statements
Free cash flow per share
-6.7189
Market cap
3.7 Million
Price to sales ratio
30.5410
Debt to equity
2.9121
Current ratio
0.7150
Income quality
0.8153
Average inventory
320 Thousand
ROE
-3.4626
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Organovo Holdings, Inc. is a biotechnology company dedicated to the development of 3D tissues that mirror critical aspects of human disease. Their innovative 3D human tissue platform features proprietary NovoGen Bioprinters, which are automated devices designed to fabricate 3D living tissues composed of mammalian cells. Additionally, the company has related technologies for preparing bio-inks and bioprinting complex multicellular tissues. As part of their offerings, they provide ExVive human liver tissue and ExVive human kidney tissue, utilized for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California. The income before tax ratio is -134.58 reflecting the pre-tax margin. The EBITDA is -$14,806,000.00 a key indicator of the company's operational profitability. Their gross profit stands at $109,000.00 highlighting the company's profitability from core operations. Furthermore, the total costs and expenses for the company are $15,195,000.00 reflecting its overall spending. The company reported selling, general, and administrative expenses of $9,644,000.00 indicating its operational overhead costs. In the investment landscape, the stock is affordable at $2.04 making it suitable for budget-conscious investors. However, it has a low average trading volume of 843,782.00 suggesting lower market activity. With a market capitalization of $3,672,000.00 the company is classified as a small-cap player. Despite this classification, it is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth. The combination of these factors indicates a dynamic position within its field, reflecting both unique opportunities and challenges pertinent to its market engagement.
What is Organovo Holdings, Inc. (ONVO)'s stock forecast?
Analysts predict Organovo Holdings, Inc. stock to fluctuate between $1.56 (low) and $21.96 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Organovo Holdings, Inc.'s market capitalization?
As of 2025-04-23, Organovo Holdings, Inc.'s market cap is $3,672,000, based on 1,800,000 outstanding shares.
How does Organovo Holdings, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Organovo Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Organovo Holdings, Inc. (ONVO) stock?
To buy Organovo Holdings, Inc. (ONVO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ONVO. Place an order (Market, Limit, etc.).
What is the best time to invest in Organovo Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Organovo Holdings, Inc. stock ever split?
Organovo Holdings, Inc.'s last stock split was 1:12 on 2025-03-21.
How did Organovo Holdings, Inc. perform in the last earnings report?
Revenue: $109,000 | EPS: -$1.60 | Growth: -19.19%.
Where can I find Organovo Holdings, Inc.'s investor relations reports?
Visit https://www.organovo.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Organovo Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Organovo Holdings, Inc. stock?
All-time high: $23.92 (2021-02-11) | All-time low: $0.32 (2024-11-15).
What are the key trends affecting Organovo Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development.
globenewswire.com
a month ago
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc.
globenewswire.com
2 months ago
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capital Market should the closing price of its common stock remain at similar levels.
globenewswire.com
2 months ago
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update.
globenewswire.com
2 months ago
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.
globenewswire.com
2 months ago
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo's common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Friday, March 21, 2025.
globenewswire.com
3 months ago
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”).
globenewswire.com
3 months ago
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.
globenewswire.com
3 months ago
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo's FXR program, including its lead asset, FXR314.
globenewswire.com
5 months ago
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.
See all news
